7-30621448-A-G
Position:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_002047.4(GARS1):āc.1415A>Gā(p.His472Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,878 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (ā ā ).
Frequency
Genomes: not found (cov: 32)
Exomes š: 6.8e-7 ( 0 hom. )
Consequence
GARS1
NM_002047.4 missense
NM_002047.4 missense
Scores
15
2
1
Clinical Significance
Conservation
PhyloP100: 9.29
Genes affected
GARS1 (HGNC:4162): (glycyl-tRNA synthetase 1) This gene encodes glycyl-tRNA synthetase, one of the aminoacyl-tRNA synthetases that charge tRNAs with their cognate amino acids. The encoded enzyme is an (alpha)2 dimer which belongs to the class II family of tRNA synthetases. It has been shown to be a target of autoantibodies in the human autoimmune diseases, polymyositis or dermatomyositis. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2015]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.992
PP5
Variant 7-30621448-A-G is Pathogenic according to our data. Variant chr7-30621448-A-G is described in ClinVar as [Pathogenic]. Clinvar id is 410314.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr7-30621448-A-G is described in Lovd as [Pathogenic]. Variant chr7-30621448-A-G is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GARS1 | NM_002047.4 | c.1415A>G | p.His472Arg | missense_variant | 11/17 | ENST00000389266.8 | NP_002038.2 | |
GARS1 | NM_001316772.1 | c.1253A>G | p.His418Arg | missense_variant | 11/17 | NP_001303701.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GARS1 | ENST00000389266.8 | c.1415A>G | p.His472Arg | missense_variant | 11/17 | 1 | NM_002047.4 | ENSP00000373918.3 | ||
GARS1 | ENST00000675651.1 | c.1415A>G | p.His472Arg | missense_variant | 11/17 | ENSP00000502513.1 | ||||
GARS1 | ENST00000675810.1 | c.1313A>G | p.His438Arg | missense_variant | 10/16 | ENSP00000502743.1 | ||||
GARS1 | ENST00000675693.1 | c.1247A>G | p.His416Arg | missense_variant | 12/18 | ENSP00000502174.1 | ||||
GARS1 | ENST00000675051.1 | c.1214A>G | p.His405Arg | missense_variant | 11/17 | ENSP00000502296.1 | ||||
GARS1 | ENST00000674815.1 | c.1046A>G | p.His349Arg | missense_variant | 11/17 | ENSP00000502799.1 | ||||
GARS1 | ENST00000674851.1 | c.1046A>G | p.His349Arg | missense_variant | 12/18 | ENSP00000502451.1 | ||||
GARS1 | ENST00000444666.6 | n.1415A>G | non_coding_transcript_exon_variant | 11/18 | 3 | ENSP00000415447.2 | ||||
GARS1 | ENST00000674616.1 | n.*1129A>G | non_coding_transcript_exon_variant | 12/18 | ENSP00000502408.1 | |||||
GARS1 | ENST00000674643.1 | n.*515A>G | non_coding_transcript_exon_variant | 12/17 | ENSP00000501636.1 | |||||
GARS1 | ENST00000674737.1 | n.*753A>G | non_coding_transcript_exon_variant | 12/18 | ENSP00000502464.1 | |||||
GARS1 | ENST00000674807.1 | n.1415A>G | non_coding_transcript_exon_variant | 11/16 | ENSP00000502814.1 | |||||
GARS1 | ENST00000675529.1 | n.*1285A>G | non_coding_transcript_exon_variant | 12/18 | ENSP00000501655.1 | |||||
GARS1 | ENST00000675859.1 | n.1415A>G | non_coding_transcript_exon_variant | 11/15 | ENSP00000502033.1 | |||||
GARS1 | ENST00000676088.1 | n.*1357A>G | non_coding_transcript_exon_variant | 13/19 | ENSP00000501884.1 | |||||
GARS1 | ENST00000676140.1 | n.*360A>G | non_coding_transcript_exon_variant | 11/17 | ENSP00000502571.1 | |||||
GARS1 | ENST00000676164.1 | n.*866A>G | non_coding_transcript_exon_variant | 11/17 | ENSP00000501986.1 | |||||
GARS1 | ENST00000676210.1 | n.*704A>G | non_coding_transcript_exon_variant | 12/18 | ENSP00000502373.1 | |||||
GARS1 | ENST00000676259.1 | n.*847A>G | non_coding_transcript_exon_variant | 11/17 | ENSP00000501980.1 | |||||
GARS1 | ENST00000676403.1 | n.1415A>G | non_coding_transcript_exon_variant | 11/16 | ENSP00000502681.1 | |||||
GARS1 | ENST00000674616.1 | n.*1129A>G | 3_prime_UTR_variant | 12/18 | ENSP00000502408.1 | |||||
GARS1 | ENST00000674643.1 | n.*515A>G | 3_prime_UTR_variant | 12/17 | ENSP00000501636.1 | |||||
GARS1 | ENST00000674737.1 | n.*753A>G | 3_prime_UTR_variant | 12/18 | ENSP00000502464.1 | |||||
GARS1 | ENST00000675529.1 | n.*1285A>G | 3_prime_UTR_variant | 12/18 | ENSP00000501655.1 | |||||
GARS1 | ENST00000676088.1 | n.*1357A>G | 3_prime_UTR_variant | 13/19 | ENSP00000501884.1 | |||||
GARS1 | ENST00000676140.1 | n.*360A>G | 3_prime_UTR_variant | 11/17 | ENSP00000502571.1 | |||||
GARS1 | ENST00000676164.1 | n.*866A>G | 3_prime_UTR_variant | 11/17 | ENSP00000501986.1 | |||||
GARS1 | ENST00000676210.1 | n.*704A>G | 3_prime_UTR_variant | 12/18 | ENSP00000502373.1 | |||||
GARS1 | ENST00000676259.1 | n.*847A>G | 3_prime_UTR_variant | 11/17 | ENSP00000501980.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461878Hom.: 0 Cov.: 31 AF XY: 0.00000138 AC XY: 1AN XY: 727240
GnomAD4 exome
AF:
AC:
1
AN:
1461878
Hom.:
Cov.:
31
AF XY:
AC XY:
1
AN XY:
727240
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:4Uncertain:3Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Neuronopathy, distal hereditary motor, type 5A Pathogenic:2
Pathogenic, no assertion criteria provided | clinical testing | Institute of Human Genetics, Cologne University | Apr 25, 2018 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Nov 01, 2014 | - - |
Charcot-Marie-Tooth disease type 2D Uncertain:1Other:1
Uncertain significance, no assertion criteria provided | literature only | Inherited Neuropathy Consortium Ii, University Of Miami | Apr 20, 2019 | - - |
not provided, no classification provided | literature only | GeneReviews | - | GARS1-HMSN (exclusively dSMA-V) [Sivakumar et al 2005, Griffin et al 2014, Cortese et al 2020, Lin et al 2020] - |
not specified Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 13, 2019 | The p.H472R variant (also known as c.1415A>G), located in coding exon 11 of the GARS gene, results from an A to G substitution at nucleotide position 1415. The histidine at codon 472 is replaced by arginine, an amino acid with highly similar properties. This variant (also referred to as p.H418R) has been reported in multiple patients with distal hereditary motor neuropathy (also called distal spinal muscular atrophy) and has been shown to segregate with disease (Sivakumar K et al. Brain, 2005 Oct;128:2304-14; Schabhüttl M et al. J. Neurol., 2014 May;261:970-82; Karakaya M et al. Hum. Mutat., 2018 09;39:1284-1298). Functional studies of this alteration demonstrate reduced aminoacylation activity, substantial reductions in yeast viability, and altered cellular localization in transfected mouse motor neuron cell lines (Griffin LB et al. Hum. Mutat., 2014 Nov;35:1363-71; Antonellis A et al. J. Neurosci., 2006 Oct;26:10397-406). In addition to the clinical data presented in the literature, this alteration is absent in population-based cohorts in the Genome Aggregation Database (gnomAD) and predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Charcot-Marie-Tooth disease type 2 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 08, 2023 | This sequence change replaces histidine, which is basic and polar, with arginine, which is basic and polar, at codon 472 of the GARS protein (p.His472Arg). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with peripheral neuropathy (PMID: 16014653, 24627108). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 410314). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on GARS protein function. Experimental studies have shown that this missense change affects GARS function (PMID: 25168514). For these reasons, this variant has been classified as Pathogenic. - |
Charcot-Marie-Tooth disease Uncertain:1
Uncertain significance, no assertion criteria provided | literature only | Inherited Neuropathy Consortium | - | - - |
Distal spinal muscular atrophy Uncertain:1
Uncertain significance, no assertion criteria provided | literature only | Inherited Neuropathy Consortium | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Pathogenic
D
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D
MetaSVM
Pathogenic
D
PrimateAI
Pathogenic
T
PROVEAN
Pathogenic
D
REVEL
Pathogenic
Sift
Pathogenic
D
Sift4G
Pathogenic
D
Polyphen
D
Vest4
MutPred
Gain of solvent accessibility (P = 0.0584);
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at